Clinical Trial Update: Neoadjuvant Nivolumab for Operable Esophageal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update on neoadjuvant nivolumab for operable esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Samsung Medical Center | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN